ConductScience.org, home

Trial · NCT03988335

A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT03988335, Phase 2, Completed, Aristea Therapeutics, Inc.; results first posted 2022-03-03

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP). Trials, record NCT03988335. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03988335

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
NCT number
NCT03988335
Status
Completed
Phases
Phase 2
Enrollment
35 participants, actual
Lead sponsor
Aristea Therapeutics, Inc.
Conditions
Palmoplantar Pustulosis
Interventions
RIST4721, Placebo
First posted
2019-06-17
Last updated
2022-04-05
Results first posted
2022-03-03

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryLog Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to BaselineBaseline to Day 28Relative change from baseline in fresh pustule count at Day 28
PrimaryLog Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to BaselineBaseline to Day 28Relative change from baseline in total pustule count at Day 28

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYLog Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to BaselineBaseline to Day 28Log transformed ratioMEAN
PRIMARYLog Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to BaselineBaseline to Day 28Log transformed ratioMEAN

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to BaselineRIST4721 300 mg0.86Standard Deviation 0.692Log transformed ratio
Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to BaselinePlacebo0.53Standard Deviation 0.561Log transformed ratio
Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to BaselineRIST4721 300 mg0.99Standard Deviation 0.667Log transformed ratio
Log Transformed Ratio of Postbaseline Total Pustule Count at Day 28 to BaselinePlacebo0.96Standard Deviation 0.672Log transformed ratio

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDRIST472116
Overall StudySTARTEDPlacebo19
Overall StudyCOMPLETEDRIST472114
Overall StudyCOMPLETEDPlacebo18
Overall StudyNOT COMPLETEDRIST47212
Overall StudyNOT COMPLETEDPlacebo1

Adverse events64

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherFatigueGeneral disordersRIST4721 300 mg1151
otherFatigueGeneral disordersPlacebo0190
otherAnxietyPsychiatric disordersRIST4721 300 mg1151
otherAnxietyPsychiatric disordersPlacebo0190
otherVaginal haemorrhageReproductive system and breast disordersRIST4721 300 mg0150
otherVaginal haemorrhageReproductive system and breast disordersPlacebo1191
otherProcedural painInjury, poisoning and procedural complicationsRIST4721 300 mg2152
otherProcedural painInjury, poisoning and procedural complicationsPlacebo1191
otherLigament sprainInjury, poisoning and procedural complicationsRIST4721 300 mg0150
otherLigament sprainInjury, poisoning and procedural complicationsPlacebo1191

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityRIST4721 300 mg015
Total, all-cause mortalityPlacebo019
Total, other adverse eventsRIST4721 300 mg1315
Total, other adverse eventsPlacebo719
Total, serious adverse eventsRIST4721 300 mg015
Total, serious adverse eventsPlacebo019

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed as
34716902DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource
RIST4721 300 mg vs Placebo: deaths from any causeTrial comparisons
RIST4721 300 mg vs Placebo: serious adverse eventsTrial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03988335

GET https://conductscience.org/api/trials/v1/NCT03988335/events?page=2